The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease

被引：19

作者：

DeWald, Lisa Evans ^{[1
,3
]}

Dyall, Julie ^{[1
]}

Sword, Jennifer M. ^{[1
]}

Torzewski, Lisa ^{[1
]}

Zhou, Huanying ^{[1
]}

Postnikova, Elena ^{[1
]}

Kollins, Erin ^{[1
]}

Alexander, Isis ^{[1
]}

Gross, Robin ^{[1
]}

Cong, Yu ^{[1
]}

Gerhardt, Dawn M. ^{[1
]}

Johnson, Reed F. ^{[2
]}

Olinger, Gene G., Jr. ^{[1
,4
]}

Holbrook, Michael R. ^{[1
]}

Hensley, Lisa E. ^{[1
]}

Jahrling, Peter B. ^{[1
,2
]}

机构：

[1] NIAID, Integrated Res Facil, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA

[2] NIAID, Emerging Viral Pathogens Sect, NIH, Frederick, MD USA

[3] Emergent BioSolut Inc, Gaithersburg, MD USA

[4] MRIGlobal Global Hlth Surveillance & Diagnost, Gaithersburg, MD USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2018年 / 218卷

关键词：

antiviral; bepridil; Marburg virus; GLYCOPROTEIN; AMIODARONE; TARGET; EBOLA;

D O I：

10.1093/infdis/jiy332

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

No therapeutics are approved for the treatment of filovirus infections. Bepridil, a calcium channel blocker developed for treating angina, was identified as a potent inhibitor of filoviruses in vitro, including Ebola and Marburg viruses, and Ebola virus in vivo. We evaluated the efficacy of bepridil in a lethal mouse model of Marburg virus disease. A dose of 12 mg/kg bepridil once or twice daily resulted in 80% or 90% survival, respectively. These data confirm bepridil's broad-spectrum anti-filovirus activity warranting further investigation of bepridil, or improved compounds with a similar mechanism, as a pan-filovirus therapeutic agent.

引用

页码：S588 / S591

页数：4

共 50 条

[21] Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease
Nutahara, K
Higashihara, E
Horie, S
Kamura, K
Tsuchiya, K
Mochizuki, T
Hosoya, T
Nakayama, T
Yamamoto, N
Higaki, Y
Shimizu, T
NEPHRON CLINICAL PRACTICE, 2005, 99 (01): : C18 - C23
[22] New Insights Into Marburg Virus Disease Pathogenesis in the Rhesus Macaque Model
Cooper, Timothy K.
Sword, Jennifer
Johnson, Joshua C.
Bonilla, Amanda
Hart, Randy
Liu, David X.
Bernbaum, John G.
Cooper, Kurt
Jahrling, Peter B.
Hensley, Lisa E.
JOURNAL OF INFECTIOUS DISEASES, 2018, 218 : S423 - S433
[23] Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension
Namba, M
Kim, S
Zhan, YM
Nakao, T
Iwao, H
HYPERTENSION RESEARCH, 2002, 25 (03) : 461 - 466
[24] Effects of Concurrent Calcium Channel Blocker on Antiplatelet Efficacy of Clopidogrel Therapy: A Systematic Review
Aggarwal, Saurabh
Loomba, Rohit S.
Arora, Rohit R.
AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (01) : E29 - E36
[25] CHRONIC HYPOXIA REDUCES THE EFFICACY OF CALCIUM-CHANNEL BLOCKER TOCOLYSIS IN-VITRO
HULL, AD
RHEE, JW
DUCSAY, CA
BIOLOGY OF REPRODUCTION, 1995, 52 : 185 - 185
[26] Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy
Joel Neutel
Ali Shojaee
Jen-Fue Maa
Advances in Therapy, 2012, 29 : 508 - 523
[27] Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy
Neutel, Joel
Shojaee, Ali
Maa, Jen-Fue
ADVANCES IN THERAPY, 2012, 29 (06) : 508 - 523
[28] A COMPARISON OF THE EFFICACY OF AN ALPHA-I-ADRENERGIC BLOCKER IN THE SLOW CALCIUM-CHANNEL BLOCKER IN THE CONTROL OF AUTONOMIC DYSREFLEXIA
LINDAN, R
LEFFLER, EJ
KEDIA, KR
PARAPLEGIA, 1985, 23 (01): : 34 - 38
[29] Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease
Mason, RP
PHARMACOTHERAPY, 2001, 21 (09): : 209S - 215S
[30] DO HYPERTENSION AND CALCIUM CHANNEL BLOCKER AGENTS INCREASE THE RISK OF PARKINSON DISEASE?
Sanyasi, R. D. L. R.
Pinzon, R.
PARKINSONISM & RELATED DISORDERS, 2018, 46 : E73 - E73

← 1 2 3 4 5 →